The relevance of modifying the vaccination strategy against Pertussis to protect infants in their first year of life

Relevance. Vaccination remains the most effective measure for controlling pertussis spread; however, immunization strategies may require revision in light of changing disease patterns.

Aims. To identify current trends in pertussis incidence in the Russian Federation and propose modifications to vaccination strategies.

Materials and methods. The study was based on analysis of statistical forms "Data on infectious and parasitic diseases" (Form No. 2) and "Data on populations of children and adults vaccinated against infectious diseases" (Form No. 6) for 2013–2025, as well as medical records of 535 infants who experienced pertussis during their first year of life in Moscow in 2023–2025.

Results. Pertussis incidence in the Russian Federation demonstrates a sustained upward trend (average annual growth rate: 9.79 %), with infants under one year remaining the most vulnerable group, accompanied by an increase in pertussis-related mortality. Against this background, a substantial proportion of cases occurs among population groups most frequently serving as sources of infection for infants: during the study period, children aged 7–14 years accounted for 33–44 % of cases, while the share of adult cases increased (17 % nationally and 31 % in Moscow in 2025), substantiating the need for national implementation of age-targeted booster vaccination. The unfavorable epidemiological situation is exacerbated by delays in infant immunization (coverage < 50 % by the end of the first year of life) and low adherence to series completion among children following natural infection (among children who experienced pertussis in 2023, only 11.2 % continued immunization; in 2024 — 50.7 %; in 2025 — 7.6 %).

Conclusions. To stabilize the situation, critical measures include: implementation of booster vaccination for school-aged children; mandatory maternal immunization to provide transplacental protection to newborns; and strict adherence to completion of vaccination series for children following pertussis infection.

1. Winter K, Zipprich J, Harriman K, Murray EL, Gornbein J, Hammer SJ, Yeganeh N, Adachi K, Cherry JD. Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study. Clin Infect Dis. 2015;61(7):1099–106. doi:10.1093/cid/civ472.

2. Lomonosova AV. Epidemiological features and main directions of surveillance and prevention of pertussis at the present stage [Internet]. 2021. Available from: https://www.sechenov.ru/upload/iblock/82a/Lomonosova.pdf (accessed: 01 Jun 2026). (In Russ.)

3. Kharit SM, Iozefovich OV, Fridman IV. Pertussis vaccine prevention: problems and possible solutions. J Infectol. 2020;12(2):50–57. doi:10.22625/2072-6732-2020-12-2-50-57. (In Russ.)

4. Briko NI, Feldbljum IV. National concept for the development of vaccine prevention in Russia. Epidemiol Vaccinoprophylaxis. 2024;(2):114–123. doi:10.31631/2073-3046-2024-23-2-114-123. (In Russ.)

5. Vaccinoprophylaxis of pertussis in children and adults: methodological recommendations / eds. Namazova-Baranova LS, Baranov AA, Briko NI. Moscow: Pediatr Publ; 2025. 92 p. (In Russ.)

6. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014;(9):CD001478. doi:10.1002/14651858.CD001478.pub6.

7. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011;204:334.e1–5. doi:10.1016/j.ajog.2010.11.024.

8. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J. 2011;30:608–10. doi:10.1097/INF.0b013e3182093814.

9. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013;32:1257–60. doi:10.1097/INF.0b013e3182a09b6a.

10. Basov AA, Vysochanskaya SO, Tsvirkun OV, Belova TR, Adugyuzelov SE, Zhernov YV, et al. Criteria for assessing the epidemiological situation of pertussis in the Russian Federation. Epidemiol Vaccinoprophylaxis. 2024;(1):4–13. doi:10.31631/2073-3046-2024-23-1-4-13. (In Russ.)

11. Basov AA, Zhernov YV, Kashutina MI, Kashkovskaya NN, Kombarova SY, Enilenis II, et al. Diphtheria, tetanus, and pertussis immunity among healthcare professionals and pregnant women in the Moscow region, Russian Federation: A preliminary cross-sectional study. Front Pediatr. 2023;11:1043707. doi:10.3389/fped.2023.1043707.

12. Amirthalingam G, Campbell H, Ribeiro S, et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis. 2016;63(Suppl 4):S236–43. doi:10.1093/cid/ciw559.

13. RLS® — National Encyclopedia of Medicines. ADACEL® (tetanus-diphtheria-acellular pertussis vaccine, adsorbed, reduced antigen content): prescribing information, composition, indications [Internet]. Available from: https://www.rlsnet.ru/drugs/adasel-89448 (accessed: 23 Jun 2026). (In Russ.)

14. Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017;64:3–8. doi:10.1093/cid/ciw634.

15. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28:8001–7. doi:10.1016/j.vaccine.2010.09.034.

16. Centers for Disease Control and Prevention. DTaP, Tdap, and Td Vaccines [Internet]. Available from: https://www.cdc.gov/vaccines/hcp/by-disease/dtap-tdap-td.html (accessed: 26 May 2026).

17. Malakhov AB, Geppe NA, Gorelov AV, Kostinov MP, Chebotareva TA, Kondyurina EG, et al. Consensus expert opinion on immunoprophylaxis of respiratory infections: XIV International Educational Consensus on Respiratory Medicine in Pediatrics. Infect Dis: News, Opin, Train. 2025;14(4):117–128. doi:10.33029/2305-3496-2025-14-4-117-128. (In Russ.)

18. Prutskova EV, Cherdantsev AP, Andreeva NP. Vaccines and vaccination against pertussis in children and adults. Infect Dis: News, Opin, Train. 2018;7(2):71–77. doi:10.24411/2305-3496-2018-12008. (In Russ.)

19. Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(RR-2). doi:10.15585/mmwr.rr6702a1.

20. Australian Immunisation Handbook. Pertussis (whooping cough) [Internet]. Available from: https://immunisationhandbook.health.gov.au/contents/vaccine-preventablediseases/pertussis-whooping-cough (accessed: 16 Jun 2026).

21. Department of Health UK. Immunisation against Infectious Diseases (The Green Book) [Internet]. London: UK Government; 2013 [updated 2016]. Available from: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book (accessed: 16 Jun 2026).

22. Hall E, Wodi AP, Hamborsky J, et al, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington, DC: Public Health Foundation; 2021.

23. Chernova TM, Timchenko VN, Pedash AI, Subbotina MD, Bulina OV, Ermakova EO, Uskova SY. Assessment of timeliness of pertussis vaccination in infants and reasons for vaccination schedule violations. J Infectol. 2021;13(2):79–86. doi:10.22625/2072-6732-2021-13-2-79-86. (In Russ.)